We evaluated somatostatin receptor scintigraphy (SRS) with (111)In-pentetreotide incremental value in pulmonary carcinoid (PC) diagnosis compared to contrast enhanced Computed Tomography (ceCT). PATIENTS AND METHODS: We enrolled 81 patients with ascertained PC, 39 at initial staging and 42 in follow-up; the primary tumor had already been excised in 68 cases. Single Photon emission Computed Tomography (SPECT) images were reconstructed with the iterative method and fused with non-enhanced Computed tomography (CT) images. RESULTS: Primary PC or metastatic lesions were ascertained in 55/81 patients and SPECT/CT was positive in 50/55 cases, while ceCT was positive in 44/55. Comparing SPECT/CT with ceCT results, we found a sensitivity of 96 vs. 87.5%, and specificity of 92% vs. 97% for the detection of primary lesion or recurrent disease. A total of 198 lesions were ascertained at SPECT/CT, while 161 at ceCT, with values of sensitivity and specificity of 85.5% and 84.6% for SRS and 75.2% and 90.5% respectively. CONCLUSION: (111)In-Pentetreotide SPECT/CT proved to be more sensitive and accurate than ceCT, thus enhancing its role in evaluating patients with PC.

Chiaravalloti, A., Spanu, A., Danieli, R., Dore, F., Piras, B., Falchi, A., et al. (2015). 111In-pentetreotide SPECT/CT in pulmonary carcinoid. ANTICANCER RESEARCH, 35(7), 4265-4270.

111In-pentetreotide SPECT/CT in pulmonary carcinoid

CHIARAVALLOTI, AGOSTINO;TAVOLOZZA, MARIO;SCHILLACI, ORAZIO
2015-01-01

Abstract

We evaluated somatostatin receptor scintigraphy (SRS) with (111)In-pentetreotide incremental value in pulmonary carcinoid (PC) diagnosis compared to contrast enhanced Computed Tomography (ceCT). PATIENTS AND METHODS: We enrolled 81 patients with ascertained PC, 39 at initial staging and 42 in follow-up; the primary tumor had already been excised in 68 cases. Single Photon emission Computed Tomography (SPECT) images were reconstructed with the iterative method and fused with non-enhanced Computed tomography (CT) images. RESULTS: Primary PC or metastatic lesions were ascertained in 55/81 patients and SPECT/CT was positive in 50/55 cases, while ceCT was positive in 44/55. Comparing SPECT/CT with ceCT results, we found a sensitivity of 96 vs. 87.5%, and specificity of 92% vs. 97% for the detection of primary lesion or recurrent disease. A total of 198 lesions were ascertained at SPECT/CT, while 161 at ceCT, with values of sensitivity and specificity of 85.5% and 84.6% for SRS and 75.2% and 90.5% respectively. CONCLUSION: (111)In-Pentetreotide SPECT/CT proved to be more sensitive and accurate than ceCT, thus enhancing its role in evaluating patients with PC.
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/36 - Diagnostica per Immagini e Radioterapia
English
Con Impact Factor ISI
111; In-pentetreotide; NET; Pulmonary carcinoid; Scintigraphy; Somatostatin receptors; SPECT;
111In-pentetreotide; NET; SPECT; pulmonary carcinoid; scintigraphy; somatostatin receptors; Aged; Carcinoid Tumor; Female; Humans; Indium Radioisotopes; Lung Neoplasms; Male; Neuroendocrine Tumors; Radiopharmaceuticals; Receptors, Somatostatin; Sensitivity and Specificity; Somatostatin; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed
http://ar.iiarjournals.org/content/35/7/4265.full.pdf+html
Chiaravalloti, A., Spanu, A., Danieli, R., Dore, F., Piras, B., Falchi, A., et al. (2015). 111In-pentetreotide SPECT/CT in pulmonary carcinoid. ANTICANCER RESEARCH, 35(7), 4265-4270.
Chiaravalloti, A; Spanu, A; Danieli, R; Dore, F; Piras, B; Falchi, A; Tavolozza, M; Madeddu, G; Schillaci, O
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
111In_Pentetreotide.pdf

accesso solo dalla rete interna

Licenza: Copyright dell'editore
Dimensione 97.77 kB
Formato Adobe PDF
97.77 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/118691
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 3
social impact